

1 **Evaluating Real-World COVID-19 Vaccine Effectiveness Using a Test-** 2 **Negative Case-Control Design**

3 By: Matthew W Reynolds (corresponding author)^a, Alex Secora^a, Alice Joules^a, Lisa Albert^a, Emma
4 Brinkley^a, Tom Kwon^a, Christina Mack^a, Stephen Toovey^b, Nancy A. Dreyer^a

5 ^aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA

6 ^bPegasus Research, Neuschwaendistrasse 6, 6390 Engelberg , Switzerland

7

8 Corresponding author full postal address:

9 3110 Fairview Park Drive, Suite 400, Falls Church, VA 22042

10

11 Authors' email addresses:

12 Matthew.Reynolds@IQVIA.com

13 Alex.Secora@IQVIA.com

14 Alice.Joules@IQVIA.com

15 Lisa.Albert@IQVIA.com

16 Emma.Brinkley@IQVIA.com

17 Tom.Kwon@IQVIA.com

18 Christina.Mack@IQVIA.com

19 Malaria@sunrise.ch [Stephen Toovey]

20 Nancy.Dreyer@IQVIA.com

21 **Abstract**

22 It is important to assess the extent to which the real-world effectiveness of marketed vaccines is consistent
23 with that observed in the clinical trials, and to characterize how well vaccines prevent COVID-19
24 symptoms. We conducted a modified test-negative design (TND) to evaluate the RW effectiveness of
25 three COVID-19 vaccines by leveraging data from an on-going, US community-based registry. Vaccine
26 effectiveness was examined in two ways: considering cases who (1) tested positive for COVID-19 (695
27 cases, 1,786 controls) and who (2) tested positive with at least one moderate/severe COVID-19 symptom
28 (165 cases, 2,316 controls). Any vaccination (full or partial) was associated with a 95% reduction in the
29 odds of having a positive COVID-19 test [adjusted odds ratio (aOR) = 0.05 (95% confidence interval
30 (CI): 0.04, 0.06)]. Full vaccination was associated with an aOR of 0.03 (95% CI: 0.03, 0.05) while partial
31 vaccination had an aOR of 0.08 (95% CI: 0.06, 0.12). Any vaccination was associated with a 71%
32 reduction in the odds of testing positive and having at least one moderate/severe symptom (aOR=0.29
33 (95% CI: 0.20, 0.40)). High effectiveness was observed across all three vaccine manufacturers both for
34 prevention of positive COVID-19 test results and prevention of moderate/severe COVID-19 symptoms.

35 **Clinicaltrials.gov NCT04368065**

36

37 **Evaluating Real World COVID-19 Vaccine Effectiveness Using a Test-** 38 **Negative Case-Control Design**

39

40 **Introduction**

41 Large-scale clinical trials evaluating the currently approved COVID-19 vaccines demonstrated robust
42 efficacy in controlled settings but there are limited data on their effectiveness under real-world conditions,
43 and in particular their effectiveness at preventing more severe symptoms associated with infection.[1-3]
44 Establishing the real-world effectiveness of COVID-19 vaccines may help promote vaccine uptake by
45 allaying concerns about the unprecedented speed at which the vaccines were developed and launched,
46 especially as new variants continue to emerge.[4]

47 One efficient method of evaluating vaccine effectiveness is the test-negative case control study design
48 (TND),[5-8], often used for studying influenza vaccines where clinical trials may not be ethical or
49 feasible, and formal testing is not routinely conducted.[9-12] They have also recently been used for
50 COVID-19 vaccine effectiveness research since TND studies have been proven to provide reliable
51 estimates of vaccine effectiveness without being subject to confounding by health care seeking
52 behavior.[13-16] These designs differ from traditional case-control study designs in that the controls are
53 distinguished from cases by testing negative for COVID-19, where both cases and controls may have
54 sought testing due to COVID-like symptoms or possible exposure to COVID-19. TND case control
55 studies are useful tools that can inform both regulatory and public health policy, especially since most of
56 the post-marketing United States (US) data on the COVID-19 vaccine effectiveness comes from
57 ecological reporting and observational studies and there is little information on their effectiveness in
58 community-dwelling, non-healthcare affiliated adults.[17-22]

59

60 We used a modified version of the TND using direct-to-patient survey data (using community reporting
61 via internet volunteers as opposed to traditional site-based recruitment) to estimate vaccine effectiveness
62 of the Moderna, Pfizer, and Janssen vaccines in the general population, including their effectiveness at
63 preventing moderate to severe COVID-19 symptoms.

64

65 **Methods**

66 This study used self-reported data from the COVID-19 Active Research Experience (CARE) registry's
67 community-based on-line registry, first launched in March, 2020 to study COVID-19 symptoms and
68 severity outside of the hospital setting and to identify what factors, if any, mitigated the risk from
69 COVID-19 (www.helpstopCOVID19.com).[23, 24] The protocol and survey were updated in January
70 2021 to include information on vaccination, regardless of whether participants had ever contracted
71 COVID-19. Participants are unpaid, recruited primarily via social media and provide informed consent
72 online. Data collection and study conduct followed all ethical principles outlined in the Declaration of
73 Helsinki for the conduct of medical research. This study was approved by an Institutional Review Board
74 and is registered at Clinicaltrials.gov NCT04368065 and EU PAS register EUPAS36240.

75 At enrollment, community-based participants report demographics, COVID-19 test results, medical
76 history, presence and severity of COVID-19-like symptoms on a 4-point scale, as well as use of
77 medications (prescription, non-prescription) and dietary supplements. In January 2021, questions were
78 added regarding COVID-19 vaccination including dates of administrations and manufacturer for each
79 vaccination.[25] Confirmation of vaccination and COVID-19 test results were not independently
80 obtained. COVID-19-related symptoms were assembled from the core FDA list[26] with some additions
81 resulting from common free text write-in responses from the surveys. These symptoms included fever,
82 chills, cough, shortness of breath/difficulty breathing, nasal congestion, sore throat, nausea, diarrhea,
83 fatigue, headache, aches and pains, runny nose, decreased sense of smell, decreased sense of taste,

84 decreased appetite, vomiting, persistent pain or pressure in the chest, trouble waking up after sleeping,
85 anxiety, feeling disoriented or having trouble thinking, depression, and insomnia or trouble sleeping.

86 We used a modified TND to evaluate the effectiveness of the COVID-19 vaccines. In contrast to a
87 traditional TND that is site-based and prospectively tests all participants at the point of care, this study
88 employs more efficient online recruitment of primarily unpaid volunteers via social media and self-
89 reporting of COVID-19 vaccines, COVID-testing, results, COVID symptoms and severity. While this is a
90 diversion from the traditional approach, these participants have more direct and immediate access to the
91 relevant COVID-testing than to testing for other infectious diseases like influenza. To ensure that the
92 study population had the potential for vaccination, we restricted these analyses to participants who
93 reported a COVID-test result between March 1 through September 16, 2021, a time-period during which
94 vaccines were widely available in the United States.

95 We approached our analysis in two ways. Our first analysis (COVID-19 case positivity) defines cases as
96 those participants who were tested for any reason and reported a positive COVID-19 test result, and
97 controls as those participants who were tested for any reason and reported a negative COVID-19 result.
98 When participants reported both positive and negative test results in that time interval, we selected the
99 positive result and classified them as a case as of that date. When they reported multiple positive tests,
100 we randomly selected one of the results as the study test result; similarly, if a participant reported multiple
101 negative results, a random result was selected and deemed the study test result. Random selection was
102 used to ensure that there was no bias implemented by always taking earlier or later tests, knowing that
103 access to vaccination increased over time starting early in 2021.

104 A second analysis incorporates the severity of self-reported COVID-like symptoms. In this analysis, cases
105 were defined as participants who reported a positive COVID-19 test result and also reported at least one
106 moderate or severe COVID-19 symptom within +/- 7 days of that test result. Controls included all
107 participants who reported a negative COVID-19 test result as well as those who reported a positive test
108 result but did not report any moderate/severe symptoms within +/- 7 days of that test result. Symptoms

109 were queried from participants at the time of positive or negative test report; when multiple surveys were
110 available within +/- 7 days of the reported COVID-test, the survey with the largest number of
111 moderate/severe symptoms reported was chosen to assure we identified the highest severity of symptoms
112 reported.

113 Participants reports were used to determine each person's vaccination status, which was subsequently
114 characterized as unvaccinated, partially vaccinated, or fully vaccinated at the time of the reported
115 COVID-test result. Unvaccinated participants had not received any vaccine at the time of the COVID-19
116 test result (Figure 1). Participants were classified as "fully vaccinated" at 14 days post-2nd dose
117 of Moderna or Pfizer vaccine or 14 days after their receipt of the Janssen vaccine. Participants were
118 classified as "partially" vaccinated if they had only received their 1st vaccination of Pfizer or Moderna
119 but not the 2nd dose, or if they had received 2 doses of Pfizer or Moderna vaccine, but were not yet 14
120 days post-2nd dose, or had received Janssen but were not yet 14 days post-vaccination. Five participants
121 who reported receiving doses from different manufacturers are treated as fully vaccinated using the same
122 time intervals described previously but were excluded from the manufacturer-specific analysis. If
123 participants noted vaccination prior to December 1, 2020 (n=10) or reported vaccination with a COVID-
124 19 vaccine other than Janssen, Pfizer, or Moderna, they were excluded from this study (n=6). Also
125 excluded were those who reported the same date for their first and second vaccine doses for Moderna and
126 Pfizer (n=8). Boosters were largely unavailable at the time these data were collected and are not
127 considered in this study.

128 The core analyses aimed to compare the exposure of vaccinated (fully or partially) vs unvaccinated, but
129 also included sensitivity analyses separately for those that were fully vaccinated vs unvaccinated and
130 partially vaccinated vs. unvaccinated. Further, each vaccine manufacture was examined separately for
131 effectiveness using the primary study vaccine exposure definition (fully or partially vaccinated vs
132 unvaccinated).

133 Access proxy was determined by defining all 50 states and District of Columbia (D.C.) into four
134 categories according to the timing of availability and the administration rate based on vaccine roll-out
135 date for the general population aged 16 and older, identified from each jurisdiction's government agency
136 website with median being the cut-off in determining high and low. High and low administration rates
137 were determined by vaccine administration per 100,000 population for each state and D.C. on June 1,
138 2021 according to CDC data[27] for COVID-19 vaccinations in the United States with the median
139 number being the cut off to determine high and low. June 1, 2021 was deemed to be a median date where
140 the majority of the United States population would have an opportunity to access vaccinations. (see Table
141 one).

142 Crude and adjusted odds ratios (95% confidence intervals) were calculated via multivariate logistic
143 regression models to examine vaccine effectiveness at preventing cases of COVID-19. Multivariate odds
144 ratios were adjusted by the following: race (white, other), gender (female, male, other [including male,
145 transgender, not disclosed, other]), age (continuous), gender (female, male, vs. other (including not
146 disclosed, other, transgender), education (some college or less, 4-year college degree, >4 year college
147 degree), ethnicity of Hispanic or Latino (yes, no), access to COVID-19 vaccine proxy (early availability,
148 high vaccination rate; early availability, low vaccination rate; late availability, high vaccination rate; late
149 availability, low vaccination rate; medical conditions including anxiety, autoimmune disorder, blood
150 disorder, cardiovascular disorder, depression, diabetes, hypertension, insomnia or trouble sleeping, kidney
151 disorder, and lung disorder (yes, no).

152

153 **Results**

154 **Participant Characteristics**

155 Of the 2,481 participants who were tested and reported vaccination status, 695 individuals reported a
156 positive COVID-19 test result and 1786 individuals reported a negative test result. Among these

157 participants, 1,211 (48.8%) were fully vaccinated, 354 (14.3%) were partially vaccinated, and 916
158 (36.9%) were unvaccinated (Table two). Most participants (80.2%) reported not having any
159 moderate/severe symptoms; 6.2% having at least one moderate to severe symptom, and 13.6% having two
160 or more such symptoms. Among participants that reported a positive COVID-19 test, 12.5% of cases
161 reported at least one moderate/severe symptom as compared to 3.75% of those reporting a negative test.
162 Study participants had a mean age of 46.4 years (Standard deviation (SD) = 15.3) and were predominately
163 female (82.8%), well educated (61.9% \geq 4-year college), and white (87.1%). Both cases and controls
164 were similar with regard to age (mean age: 46.7(SD= 15.3) vs. 46.3(SD = 15.0)), gender (female 80.7%
165 vs 83.7%), and race (white: 89.5% vs 86.2%), but the case population (52.5% \geq 4-year college) reported
166 slightly higher education than controls (61.9% \geq 4-year college). A notable proportion of the study
167 participants reported having anxiety (38.5%), depression (32.5%), insomnia or trouble sleeping (29.8%),
168 and/or hypertension (22.6%) at their baseline survey, which were comparable across both cases and
169 controls.

170 **Test Negative Design Analysis**

171 For the first analysis, which focused on evaluating COVID-19 vaccine effectiveness at preventing a
172 COVID-19 positive test, 124 cases (17.8% of 695) reported being fully or partially vaccinated at the time
173 of their positive COVID-19 test, while 1441 controls (80.6% of 1,786) reported being fully or partially
174 vaccinated at the time of their negative COVID-19 test (Table two). This resulted in an unadjusted odds
175 ratio (aOR) of 0.05 (95% CI: 0.04, 0.07) and adjusted odds ratio of 0.05 (95% CI: 0.04, 0.06), indicating
176 that being vaccinated was associated with a 95% reduction in the odds of having a positive COVID-19
177 test.

178 The second analysis focused on evaluating the effectiveness of preventing at least one moderate/severe
179 COVID-19 symptom in COVID-19 positive cases and included 165 cases and 2,316 controls (Table
180 three). Fifty-seven cases reported being fully or partially vaccinated at the time of their positive COVID-
181 19 test with at least one moderate/severe symptom, while 1547 control patients reported being fully or

182 partially vaccinated at the time of their negative COVID-19 test with at least on moderate/severe
183 symptom. This resulted in an unadjusted odds ratio of 0.26 (95% CI: 0.19, 0.37) and adjusted odds ratio
184 of 0.29 (95% CI: 0.20, 0.40), indicating a 71% reduction in the odds of having a positive COVID-19 test
185 and at least one moderate/severe symptom.

186 When examining the effects of covariates on reporting a positive test for COVID-19, male gender (OR
187 1.50; 95% CI: 1.10, 2.06), white race (OR 2.33; 95% CI: 1.64, 3.32), reporting a blood disorder,
188 (including a history of blood clots, sickle cell disease, thalassemia, thrombocytopenia, or other blood
189 disease), (OR 3.01; 95% CI: 1.56, 5.83), and reporting a lung disorder (OR 0.55, 95% CI: 0.37, 0.81)
190 were significant predictors in the multivariate model. While not statistically significant, low vaccination
191 rates in the state of the participant, regardless of timing of vaccine availability were suggestive of
192 increased risk of COVID-19 positive testing (early availability/low access = OR 1.24; 95% CI: 0.74, 2.09;
193 and late availability/low access = OR 1.26; 95% CI 0.79, 2.02).

194 When examining the effectiveness of full vaccination (versus being unvaccinated) and partial vaccination
195 (at least one dose, but not having achieved full potential immunity) versus being unvaccinated, full
196 vaccination was more protective (aOR=0.03, 95% CI: 0.03, 0.05) when compared to partial vaccination
197 (versus being unvaccinated) (aOR=0.08, 95% CI: 0.06, 0.12) (Table four). In the symptom-based
198 analysis, fully vaccination (aOR=0.28, 95% CI: 0.19, 0.41)) resulted in slightly better effectiveness than
199 those with partial vaccination (aOR=0.29, 95% CI: 0.16, 0.53).

200 A manufacturer-specific test negative design analysis was also conducted via both case definitions. When
201 examining COVID-19 test positivity alone, vaccine effectiveness results were similar across
202 manufacturers, conveying significant protection against COVID-19 infection (Table five and Figure two).
203 Moderna had the highest effectiveness via Odds Ratios (97%, aOR=0.03, 95% CI: 0.02, 0.04), followed
204 closely by Janssen at 96% (aOR=0.04, 95% CI: 0.02, 0.09), and Pfizer BioNTech at 94% (aOR=0.06,
205 95% CI: 0.04, 0.07). When examining by the symptom severity case definition, Moderna showed the best
206 results at preventing symptomatic cases with an 86% effectiveness (aOR=0.14, 95% CI: 0.07, 0.28),

207 followed by Janssen at 65% (aOR=0.35, 95% CI: 0.11, 1.15) and Pfizer at 62% (aOR=0.38, 95% CI:
208 0.24, 0.58).

209

210 **Discussion**

211 While the COVID-19 vaccines were tested through clinical trials establishing their safety and efficacy,
212 the expedited clinical development coupled with immediate widespread use has brought scrutiny from the
213 public as to whether the findings would be replicated in the real-world. Here we show that COVID-19
214 vaccines manufactured by Pfizer BioNTech, Janssen, and Moderna demonstrated consistent and
215 meaningful real-world effectiveness. The results from this community-based registry of US adults are
216 consistent with what has been reported in randomized controlled trials[1-3] as well as other published
217 TND studies from both ambulatory and inpatient settings.[13-16] We observed a 95% reduction in odds
218 of a COVID-19 positive test in vaccinated participants, with 94%, 96%, and 97% reduction in odds for
219 Pfizer BioNTech, Janssen, and Moderna, respectively. With respect to vaccine effectiveness at mitigating
220 disease severity, we observed a 74% reduction in risk of moderate-to-severe cases overall. Our results
221 suggest greater protection for those who were fully vaccinated as compared to those partially vaccinated,
222 although the results still show clear protection for patients who only received one mRNA vaccine dose
223 and/or had not completed the full immunity period (i.e., 14 days post-final vaccination). These findings
224 contribute to the evidence supporting COVID-19 vaccine effectiveness at mitigating infection in the
225 community overall and also reducing COVID-19 severity among breakthrough infections.

226 Since their emergency use authorizations, several cohort studies among healthcare workers and among
227 older adults have shown effectiveness of the mRNA vaccines (i.e., Pfizer and Moderna) consistent with
228 the 94-95% efficacy observed Phase III studies.[17, 19, 22] TND studies have also been conducted in
229 similar high-risk groups from the U.S., U.K., and Canada, with consistent findings.[13-16] At the same
230 time, there are still limited data on vaccine effectiveness among community-dwelling adults across age

231 groups, particularly for those receiving the Janssen vaccine. Our results generally align with other cohort
232 and case-control studies in terms of further demonstration of vaccine effectiveness in the general
233 population. Of note, our findings with respect to mRNA vaccine effectiveness appear very close to what
234 was observed in the Phase II studies other than for the Janssen vaccine (96.0% effective in this study
235 versus 66.3% in the clinical trial).

236 Our study also contributes to the broader understanding of vaccine effectiveness at mitigating moderate to
237 severe COVID-19 disease symptoms. While we observed the strongest effectiveness in the context of
238 preventing a positive test, these COVID-19 vaccines had substantial (~70%) effectiveness in preventing
239 one or more moderate to severe symptoms, noting that the severity of COVID-19 symptoms here requires
240 self-reporting, which may be difficult from a hospital bed or among very sick patients, and had no
241 requirement for or link to healthcare utilization (this study only included 21 participants that reported any
242 hospitalizations during the study period). Our findings show that COVID-19 vaccines protect against
243 moderate-to severe symptoms that did not necessarily require hospitalization or even interactions with the
244 healthcare system.

245 While vaccination status was clearly the most important variable in the multivariate models at explaining
246 the risk of a positive COVID-19 test, there were several other variables that were significant and may
247 provide insight into the bigger picture of COVID-19 risk and vaccine effectiveness. Participants who
248 reported a blood disorder in their baseline medical history were associated with a 3-fold risk of testing
249 positive for COVID-19. This blood disorder variable is broad, with our 66 respondents having been
250 prompted by examples that included blood clots, sickle cell disease, thalassemia, thrombocytopenia, or
251 other blood disease. Our finding in this heterogenous group requires some explanation. While it is known
252 that COVID-19 infection may be pro-thrombotic, and this may potentially exacerbate pro-thrombotic
253 blood disorders, our broad and heterogenous ‘blood disorder’ group may also have included conditions
254 associated with immunosuppression, or the use of immunosuppressive medications, in turn resulting in
255 decreased viral clearance and more severe disease. This result may highlight another potential at-risk

256 population for increased risk of the COVID-19 infection, and merits further investigation to better define
257 the hematological conditions associated with greater risk. Anaemia has been previously suggested to be
258 an independent risk factor for Covid-19 related mortality, and it would be very likely that our group also
259 included anaemic patients, but their exact contribution to the rather large effect observed is uncertain in
260 our data set. [28, 29] Also, being Caucasian was associated here with a more than a twofold increased risk
261 of testing COVID-19 positive, but no elevated risk of testing positive and being symptomatic; however,
262 we suspect that white race may actually be serving here as a proxy for access to COVID-19 testing rather
263 than having a direct causal relationship.

264 In contrast, participants who reported lung disorders were significantly less likely to test positive for
265 COVID-19 (aOR = 0.55; 95% CI: 0.37, 0.81). It is possible that there may be a common drug/treatment in
266 this group of participants that maybe be COVID-19 protective, but it also makes sense that those at
267 highest risk of severe COVID-19 outcomes may embark on other effective methods at preventing
268 COVID-19 (such as social isolation, etc.), that are not explicitly captured as stand-alone variables in our
269 model. These social variables also play an important role in explaining COVID-19 transmission outside
270 of vaccination, and they should be considered when possible in other studies.

271 It was also seen that while early availability of the vaccine in the participants' home states did not have a
272 notable impact, the level of vaccinations in those states did seem to suggest some association with testing
273 positive. Low vaccination rates in the state of the participant, regardless of timing of vaccine availability,
274 show a modest increased risk of COVID-19 positive testing (early availability/low access = OR 1.24;
275 95% CI: 0.74, 2.09; and late availability/low access = OR 1.26; 95% CI 0.79, 2.02). This suggests that
276 independent of the study participant's personal vaccination status, if the state in which they live was in the
277 lower half of vaccination rates, their risk of being a COVID-19 positive case was approximately 25%
278 higher. This clearly suggests that increasing the vaccination rate in the population has a beneficial effect
279 at preventing COVID-19 transmission.

280 While the data are reassuring on the effectiveness of the current COVID-19 vaccines, those vaccinated
281 may not be as strongly protected against emerging variants such as delta and omicron. Coupled with the
282 known possibility of waning immunity from vaccination, additional booster doses are now recommended,
283 particularly for higher risk groups. While cohort studies can be limited when timely data are needed to
284 inform public health measures, the efficiency of a TND or modified TND approach with an unbiased
285 selection of cases and controls are likely one of the best options to study the vaccines in the post-market
286 setting.

287 Although CARE data rely on self-reported information subject to some information biases, these real-
288 world data have detailed information on participant experiences with respect to COVID-19 and the
289 vaccines. Misclassification of vaccination status can bias TND studies, but is unlikely here since CARE
290 participants are likely to know whether they have been vaccinated and were encouraged to consult their
291 vaccination cards when reporting manufacturer, lot and dates. Moreover, person-generated data like this
292 allows for a comprehensive capture of all relevant patient-level clinical and nonclinical data which are
293 often not available in larger real world data sources. At the same time, it is not always clear whether
294 participants were tested for COVID-19 because they were symptomatic or exposed to someone who
295 tested positive, or if it was mandated for some other reason. It is possible that vaccinated individuals are
296 more likely to take a COVID-19 test out of caution, whereas unvaccinated individuals are not concerned
297 about COVID-19, driving their unvaccinated status., which could bias TND studies if testing practices
298 were differentially affected by vaccination status. While the study was conducted in a period not affected
299 by the more transmissible Delta and Omicron variants, we chose a period that reflects the circulating virus
300 during the Phase III clinical trials to assess consistency of results. This approach, design, and data
301 collection could also be implemented and/or re-directed in an efficient and effective manner for new and
302 emerging COVID-19 vaccine and treatment effectiveness questions.

303

304

305 **Ethics approval and informed consent**

306 This study was approved by Institutional Review Board and registered at Clinicaltrials.gov

307 NCT04368065 and EU PAS register EUPAS36240. All participants provided informed consent online.

308 **Consent for publication**

309 Consent for publication of research finding was provided online.

310 **Data availability**

311 Due to data privacy and security regulations the researchers are not able to share participant level data.

312 **Funding**

313 This work was supported in part by a contract with the US Food and Drug Administration. The bulk of

314 the funding was provided by IQVIA.

315 **Conflict of interests**

316 The authors declare that they have no known competing financial interests or personal relationships that

317 could have appeared to influence the work reported in this paper.

318 **Table one: Access proxy defined as matrix of availability and vaccine administration rate**

	High Vaccination Rate (Admin per 100k on 6/1*)	Low Vaccination Rate (Admin per 100k on 6/1*)
Early Availability (March 10 – April 2)	CT, NH, CO, MN, IL, OH, AZ, MT, UT, ND, KS (>79,938) Count: 11	TX, IN, OK, WV, SC, GA, AR, WY, LA, AL, MS (<79,938) Count: 11
Late Availability (April 5 – April 19)	VT, MA, HI, DC, ME, RI, NM, NJ, MD, NY, WA, PA, VA, CA, DE (>96,910) Count: 15	OR, WI, IA, NE, SD, FL, MI, AK, KY, NV, NC, MO, TN, ID (<96,910) Count: 14

319

320

321 **Table two. Participant characteristics**

	Cases COVID-19 test positive N=695	Controls COVID-19 test negative N=1786	Cases COVID-19 test positive with >1 moderate to severe COVID symptoms N=165	Controls COVID-19 test positive with <1 moderate to severe COVID symptoms & COVID-19 test negative N=2316	Total N=2481
Vaccination Status (N)	695	1786	165	2316	2481
Fully Vaccinated	76 (10.9)	1135 (63.6)	42 (25.5)	1199 (51.8)	1211 (48.8)
Partially Vaccinated	48 (6.9)	306 (17.1)	15 (9.1)	348 (15.0)	354 (14.3)
Unvaccinated	571 (82.2)	345 (19.3)	108 (65.5)	769 (33.2)	916 (36.9)
Number of Moderate/Severe Symptoms					
None	431 (62.0)	1559 (87.3)	0 (0)	1991 (85.9)	1990 (80.2)
One	87 (12.5)	67 (3.75)	54 (32.7)	99 (4.3)	154 (6.2)
Two or more	177 (25.5)	160 (8.9)	111 (67.3)	226 (9.8)	337 (13.6)
Age in years (N)	695	1786	165	2316	2481
Mean (SD)	46.7 (15.3)	46.3 (15.0)	46.7 (15.2)	46.3 (15.1)	46.4 (15.1)
Median [IQR]	46 (34 – 60)	45 (34 – 59)	46 (34 – 59)	45 (34 – 59)	45 (34 – 59)
Age Group (years)	695	1786	165	2316	2481
18-29	93 (13.4)	248 (13.9)	35 (21.2)	573 (24.7)	341 (13.74)
30-39	164 (23.6)	444 (24.8)	27 (16.4)	433 (18.7)	608 (24.5)
40-49	123 (17.7)	337 (18.9)	45 (27.3)	416 (17.9)	460 (18.5)
50-59	139 (20.0)	322 (18.0)	39 (23.6)	572 (24.7)	461 (18.6)
>=60	176 (25.3)	435 (24.4)	19 (11.5)	322 (13.9)	611 (24.6)
Gender	695	1786	165	2316	2481
Female	561 (80.7)	1495 (83.7)	135 (81.8)	1921 (82.9)	2056 (82.8)
Male	118 (16.9)	244 (13.7)	25 (15.2)	337 (14.6)	362 (14.6)
Transgender	7 (1.0)	26 (1.5)	2 (1.2)	31 (1.3)	33 (1.3)
Other	9 (1.3)	20 (1.5)	3 (1.8)	26 (1.1)	29 (1.2)
Not Disclosed	0 (0)	1 (0.1)	0 (0)	1 (0.04)	1 (0.04)
Education	695	1784	165	2314	2479
Some college or less	330 (47.5)	614 (34.4)	88 (53.3)	856 (37.0)	944 (38.1)
4-yr college degree	157 (22.6)	491 (27.5)	36 (21.8)	612 (26.4)	648 (26.1)
>4yr college degree	208 (29.9)	679 (38.1)	41 (24.9)	846 (36.5)	887 (35.8)
Race	692	1783	1 (0.6)	53 (2.3)	2481

	Cases COVID-19 test positive N=695	Controls COVID-19 test negative N=1786	Cases COVID-19 test positive with >1 moderate to severe COVID symptoms N=165	Controls COVID-19 test positive with <1 moderate to severe COVID symptoms & COVID-19 test negative N=2316	Total N=2481
Asian	5 (0.7)	49 (2.8)	2 (1.2)	81 (3.5)	54 (2.2)
Black or African American	24 (3.5)	59 (3.3)	143 (86.7)	2013 (86.9)	83 (3.4)
White	619 (89.5)	1537 (86.2)	18 (10.9)	164 (7.1)	2156 (87.1)
Other**	44 (6.4)	138 (7.7)	1 (0.6)	5 (0.2)	182 (7.4)
Ethnicity					
Hispanic or Latino	73 (10.6)	154 (8.7)	14 (8.5)	213 (9.2)	227 (9.2)
Medical Conditions					
Anxiety	289 (41.5)	666 (37.3)	84 (50.9)	871 (37.6)	955 (38.5)
Autoimmune disease	90 (13.0)	214 (11.9)	27 (16.3)	277 (11.9)	304 (12.3)
Blood disorder	30 (4.3)	36 (2.0)	54 (2.3)	12 (7.3)	66 (2.7)
Cardiovascular disease	39 (5.6)	100 (5.6)	14 (8.5)	125 (5.4)	139 (5.6)
Depression	239 (34.4)	567 (31.8)	69 (41.8)	737 (31.8)	806 (32.5)
Diabetes	65 (9.4)	151 (8.5)	15 (9.1)	201 (8.7)	216 (8.7)
Hypertension	158 (22.7)	402 (22.5)	40 (24.2)	520 (22.5)	560 (22.6)
Insomnia or trouble sleeping	225 (32.4)	515 (28.8)	72 (43.6)	668 (28.8)	740 (29.8)
Kidney disease	21 (3.02)	53 (3.0)	6 (3.6)	68 (2.9)	74 (3.0)
Lung disease	63 (9.06)	204 (11.4)	21 (12.7)	246 (10.6)	267 (10.7)
Organ transplant	2 (0.3)	3 (0.2)	1 (0.6)	4 (0.2)	5 (0.2)
On Treatment for Cancer?					
Yes	692 10 (1.5)	1777 22 (1.2)	5 (3.0)	27 (1.2)	2469 32 (1.3)

322

* The race category of other includes: 13 American Indians or Alaskans, 3 Hawaiian or Pacific Islander, 77 who selected multiple races and 89 who selected 'other'.

323 **Table three. Multivariate model for vaccine effectiveness at preventing cases of COVID-19**

Covariates	Odds of having a COVID-19 positive test	Odds of having a COVID-19 positive test with ≥ 1 moderate/severe symptom)
	Adjusted OR (95% CI)	Adjusted OR (95% CI)
Vaccination Status		
Unvaccinated	(ref)	(ref)
Fully or Partially Vaccinated	0.05 (0.04, 0.06)	0.29 (0.20, 0.40)
Anxiety	1.27 (0.96, 1.69)	1.46 (0.97, 2.21)
Autoimmune Disorder	1.22 (0.86, 1.74)	1.15 (0.72, 1.85)
Blood Disorder	3.01 (1.56, 5.83)	2.60 (1.28, 5.28)
Cardiovascular Disorder	0.89 (0.53, 1.50)	1.47 (0.76, 2.81)
Depression	1.00 (0.74, 1.33)	1.07 (0.71, 1.61)
Diabetes	1.23 (0.81, 1.86)	0.87 (0.48, 1.58)
Hypertension	0.89 (0.66, 1.20)	0.85 (0.55, 1.32)
Insomnia or trouble sleeping	1.09 (0.84, 1.42)	1.57 (1.09, 2.25)
Kidney Disorder	1.19 (0.60, 2.36)	0.95 (0.38, 2.42)
Lung Disorder	0.55 (0.37, 0.81)	0.90 (0.54, 1.52)
Education		
Some college or less	(ref)	(ref)
4 years of college	0.73 (0.55, 0.97)	0.71 (0.46, 1.08)
More than 4 years of college	0.97 (0.74, 1.27)	0.68 (0.45, 1.02)
Race		
Other	(ref)	(ref)
White	2.33 (1.64, 3.32)	1.09 (0.65, 1.82)
Age (per 1 year increment)	1.00 (0.99, 1.01)	1.01 (0.99, 1.02)
Gender		
Female	(ref)	(ref)
Male	1.50 (1.10, 2.06)	1.26 (0.79, 2.01)
Other	1.35 (0.63, 2.91)	1.29 (0.48, 3.47)
Ethnicity (Hispanic Latino vs. Not)		
Not Hispanic	(ref)	(ref)
Hispanic	0.99 (0.68, 1.46)	0.84 (0.45, 1.54)
Vaccination Access (Proxy)		
Early availability, high vaccination rate	(ref)	(ref)
Early availability, low vaccination rate	0.87 (0.60, 1.26)	1.24 (0.74, 2.09)
Late availability, high vaccination rate	0.63 (0.46, 0.86)	0.72 (0.44, 1.16)
Late availability, low vaccination rate	1.15 (0.83, 1.60)	1.26 (0.79, 2.02)

Note: If a referent category is not listed, then the comparison is Yes vs. No (referent group).

324
325

326 **Table four. Test negative analysis (odds of a positive COVID-19 test or a positive COVID-19 test**
 327 **and at least one moderate to severe symptom by vaccination status**

Test negative analysis based on COVID-19 test results	Vaccination Status	Cases COVID-19 test positive	Controls COVID-19 test negative	OR (95% CI)	aOR (95% CI)
	Fully Vaccinated	76	1135	0.04 (0.03, 0.05)	0.03 (0.03, 0.05)
	Unvaccinated	571	345		
	Partially Vaccinated	48	306	0.10 (0.07, 0.13)	0.08 (0.06, 0.12)
	Unvaccinated	571	345		
Test negative analysis based on COVID-19 test results and requiring at least one moderate to severe symptom	Vaccination Status	Cases COVID-19 test positive with >1 moderate to severe COVID symptoms	Controls COVID-19 test positive with <1 moderate to severe COVID symptoms & COVID-19 test negative	OR (95% CI)	aOR (95% CI)
	Fully vaccinated	42	1199	0.25 (0.17, 0.36)	0.28 (0.19, 0.41)
	Unvaccinated	108	769		
	Partially vaccinated	15	348	0.31 (0.18, 0.53)	0.29 (0.16, 0.53)
	Unvaccinated	108	769		


328

329 **Table five. Vaccine effectiveness at preventing cases of COVID-19 by vaccine manufacturer and**
 330 **vaccination status for both test negative analysis results**

Test negative analysis based on COVID-19 test results	Manufacturer	Vaccination Status	Cases COVID-19 test positive	Controls COVID-19 test negative	OR (95% CI)	aOR (95% CI)
	Test negative analysis based on COVID-19 test results and requiring at least one moderate to severe symptom	Pfizer	Fully or Partially Vaccinated	80	732	0.06 (0.05, 0.09)
Unvaccinated			571	345		
Moderna		Fully or Partially Vaccinated	37	611	0.04 (0.03, 0.05)	0.03 (0.02, 0.04)
		Unvaccinated	571	345		
Janssen		Fully or Partially Vaccinated	7	93	0.05 (0.02, 0.09)	0.04 (0.02, 0.09)
		Unvaccinated	571	345		
Test negative analysis based on COVID-19 test results and requiring at least one moderate to severe symptom	Manufacturer	Vaccination Status	Cases COVID-19 test positive with >1 moderate to severe COVID symptoms	Controls COVID-19 test positive with <1 moderate to severe COVID symptoms & COVID-19 test negative	OR (95% CI)	aOR (95% CI)
	Pfizer	Fully or Partially Vaccinated	30	620	0.35 (0.23, 0.52)	0.38 (0.24, 0.58)
		Unvaccinated	108	769		
	Moderna	Fully or Partially Vaccinated	9	495	0.13 (0.07, 0.26)	0.14 (0.07, 0.28)
		Unvaccinated	108	769		
	Janssen	Fully or Partially Vaccinated	3	83	0.26 (0.08, 0.83)	0.35 (0.11, 1.15)
Unvaccinated		108	769			

331
 332
 333


334 **Figure one. Vaccination status determination at time of COVID-19 testing for single dose and two**
335 **dose vaccines**



336

337


338 **Figure two. Vaccine effectiveness of preventing cases of COVID-19 among those with at least one**
339 **vaccination vs unvaccinated, overall and by manufacturer (primary analysis based on COVID-19**
340 **test results)**



341

342 **Figure three. Vaccine effectiveness of preventing cases of COVID-19 among those with at least one**
 343 **vaccination vs unvaccinated, overall and by manufacturer (secondary analysis based on test results**
 344 **and requiring at least one moderate to severe symptom)**

Vaccine	Effectiveness
Overall	71% (60-80%)
Pfizer	63% (44-75%)
Moderna	83% (70-90%)
J&J	73% (11-92%)



345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359

360 References

- 361 (1) **Baden LR, et al.** Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*
362 2021; **384**(5): 403-416.
- 363 (2) **Polack FP, et al.** Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*
364 2020; **383**(27): 2603-2615.
- 365 (3) **Sadoff J, et al.** Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N*
366 *Engl J Med* 2021; **384**(23): 2187-2201.
- 367 (4) **Patel MM, Jackson ML, Ferdinands J.** Postlicensure Evaluation of COVID-19 Vaccines.
368 *JAMA* 2020; **324**(19): 1939-1940.
- 369 (5) **Chua H, et al.** The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A
370 Systematic Review of Methodology. *Epidemiology* 2020; **31**(1): 43-64.
- 371 (6) **Dean NE, Hogan JW, Schnitzer ME.** Covid-19 Vaccine Effectiveness and the Test-Negative
372 Design. *N Engl J Med* 2021; **385**(15): 1431-1433.
- 373 (7) **Organization WH.** Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March
374 2021: World Health Organization; 2021.
- 375 (8) **Organization WH.** Estimating COVID-19 vaccine effectiveness against severe acute respiratory
376 infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2: an evaluation
377 using the test-negative design: guidance document: World Health Organization. Regional Office for
378 Europe; 2021.
- 379 (9) **Feng S, et al.** Estimating Influenza Vaccine Effectiveness With the Test-Negative Design Using
380 Alternative Control Groups: A Systematic Review and Meta-Analysis. *Am J Epidemiol* 2018; **187**(2):
381 389-397.
- 382 (10) **Fukushima W, Hirota Y.** Basic principles of test-negative design in evaluating influenza
383 vaccine effectiveness. *Vaccine* 2017; **35**(36): 4796-4800.
- 384 (11) **Shi M, et al.** A comparison of the test-negative and the traditional case-control study designs for
385 estimation of influenza vaccine effectiveness under nonrandom vaccination. *BMC Infect Dis* 2017; **17**(1):
386 757.
- 387 (12) **Vasileiou E, et al.** Seasonal Influenza Vaccine Effectiveness in People With Asthma: A National
388 Test-Negative Design Case-Control Study. *Clin Infect Dis* 2020; **71**(7): e94-e104.
- 389 (13) **Lopez Bernal J, et al.** Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines
390 on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative
391 case-control study. *BMJ* 2021; **373**: n1088.
- 392 (14) **Chung H, et al.** Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against
393 symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative
394 design study. *BMJ* 2021; **374**: n1943.
- 395 (15) **Thompson MG, et al.** Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care
396 Settings. *N Engl J Med* 2021; **385**(15): 1355-1371.
- 397 (16) **Pilishvili T, et al.** Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna
398 COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. *MMWR Morb*
399 *Mortal Wkly Rep* 2021; **70**(20): 753-758.
- 400 (17) **Fowlkes A, et al.** Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection
401 Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S.
402 Locations, December 2020-August 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(34): 1167-1169.
- 403 (18) **Kow CS, Hasan SS.** Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of
404 large observational studies. *Inflammopharmacology* 2021; **29**(4): 1075-1090.
- 405 (19) **Swift MD, et al.** Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19)
406 Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a
407 Cohort of Healthcare Personnel. *Clin Infect Dis* 2021; **73**(6): e1376-e1379.

- 408 (20) **Britton A, et al.** Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of
409 Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-
410 February 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(11): 396-401.
- 411 (21) **Tenforde MW, et al.** Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-
412 19 Among Hospitalized Adults Aged ≥ 65 Years - United States, January-March 2021. *MMWR Morb*
413 *Mortal Wkly Rep* 2021; **70**(18): 674-679.
- 414 (22) **Thompson MG, et al.** Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-
415 1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First
416 Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March
417 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(13): 495-500.
- 418 (23) **Dreyer NA, et al.** Self-reported symptoms from exposure to Covid-19 provide support to clinical
419 diagnosis, triage and prognosis: An exploratory analysis. *Travel Med Infect Dis* 2020; **38**: 101909.
- 420 (24) **Dreyer N, et al.** Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2
421 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19. *Int J Gen Med* 2021;
422 **14**: 3941-3949.
- 423 (25) **Dreyer NA, et al.** How frequent are acute reactions to COVID-19 vaccination and who is at risk?
424 *medRxiv* 2021: 2021.2010.2014.21265010.
- 425 (26) United States Food and Drug Administration. Assessing COVID-19-Related Symptoms in
426 Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for
427 COVID-19 Prevention or Treatment. In, 2020.
- 428 (27) Center for Disease Control and Prevention. COVID-19 Vaccinations in the United States. In,
429 2021.
- 430 (28) **Roy NBA, et al.** Protecting vulnerable patients with inherited anaemias from unnecessary death
431 during the COVID-19 pandemic. *Br J Haematol* 2020; **189**(4): 635-639.
- 432 (29) **Tremblay D, et al.** Mild anemia as a single independent predictor of mortality in patients with
433 COVID-19. *EJHaem* 2021.

434